Pharmaceuticals

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

China SXT Pharma secured $9 million in a direct offering, but a catastrophic stock collapse reveals deep investor distrust in its survival strategy.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

Samsung Bioepis's latest report reveals a thriving biosimilar market, yet deep-seated policy debates over the 340B program threaten to disrupt growth.

Viking Therapeutics' appointment of digital health veteran Dorothy Gemmell signals a pivotal shift from lab to market in the crowded weight-loss field.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

A new report reveals a seismic shift in drug manufacturing. Forget massive factories; the real power now lies with a handful of specialists building our medical future.

As the pet care market booms, Exubrion Therapeutics appoints a new CCO to expand its groundbreaking, single-injection arthritis treatment for dogs.

After its stock mysteriously surged over 2,000% intraday, China Pharma announced a $5M offering at a steep discount. A strategic move or a sign of strain?

Acclaimed scientist Michael Ehlers leaves big pharma's orbit for an AI startup. It's more than a career move; it's a test of whether technology can fix our broken drug development system.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.

With a proven record in biosimilars, new President Dominic Bégin is set to deepen Organon's impact on women's health and healthcare affordability in Canada.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.

While debates over UN dues persist, American companies quietly secured over $2 billion in UN contracts, turning global initiatives into a major revenue stream.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

A $15.97M federal grant will help Virginia's APM Tech Hub create a fully domestic drug supply chain, tackling critical shortages and boosting US manufacturing.